❌

Normal view

  • ✇STAT
  • STAT+: In a banner year for biopharma, here are the best industry CEOs of 2025 Adam Feuerstein
    In an exceptional year for biotech and pharma, there were so many outstanding CEOs, I couldn’t single out just one for my 2025 Best Biopharma CEO honor. Here are this year’s winners:  The dealmakers  2025 has been the best year for biotechs being acquired by pharma companies since 2019, with nearly $240 billion worth of deals announced or closed through November, according to Stifel.Continue to STAT+ to read the full story…
     

STAT+: In a banner year for biopharma, here are the best industry CEOs of 2025

16 December 2025 at 17:30

In an exceptional year for biotech and pharma, there were so many outstanding CEOs, I couldn’t single out just one for my 2025 Best Biopharma CEO honor.

Here are this year’s winners: 

The dealmakers 

2025 has been the best year for biotechs being acquired by pharma companies since 2019, with nearly $240 billion worth of deals announced or closed through November, according to Stifel.

Continue to STAT+ to read the full story…

© Hyacinth Empinado/STAT

  • ✇STAT
  • STAT+: Biotech might be tiny but the dealmaking is mighty Adam Feuerstein
    This story first appeared in Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox. Nvidia’s market value topped $5 trillion this week.  The total market value of ALL pharma and biotech companies is $4.6 trillion.Continue to STAT+ to read the full story…
     

STAT+: Biotech might be tiny but the dealmaking is mighty

30 October 2025 at 18:30

This story first appeared in Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox.

Nvidia’s market value topped $5 trillion this week. 

The total market value of ALL pharma and biotech companies is $4.6 trillion.

Continue to STAT+ to read the full story…

© Molly Ferguson/STAT

❌